Solid Biosciences (SLDB) Revenue & Revenue Breakdown
Solid Biosciences Revenue Highlights
Solid Biosciences Revenue by Period
Solid Biosciences Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | - | -100.00% |
| 2022-12-31 | $8.09M | -40.57% |
| 2021-12-31 | $13.62M | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2016-12-31 | - | 100.00% |
| 2015-12-31 | - | - |
Solid Biosciences generated - in revenue during NA 2023, up -100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
Solid Biosciences Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | - | 100.00% |
| 2024-03-31 | - | -100.00% |
| 2023-12-31 | $4.74M | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | -100.00% |
| 2022-12-31 | $8.09M | 100.00% |
| 2022-09-30 | - | -100.00% |
| 2022-06-30 | $6.17M | 220.47% |
| 2022-03-31 | $1.93M | -38.97% |
| 2021-12-31 | $3.15M | -10.83% |
| 2021-09-30 | $3.54M | -1.59% |
| 2021-06-30 | $3.59M | 7.77% |
| 2021-03-31 | $3.33M | -96.61% |
| 2020-12-31 | $98.32M | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2018-09-30 | - | 100.00% |
| 2018-06-30 | - | 100.00% |
| 2018-03-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2017-09-30 | - | 100.00% |
| 2017-06-30 | - | 100.00% |
| 2017-03-31 | - | 100.00% |
| 2016-12-31 | - | - |
Solid Biosciences generated - in revenue during Q2 2024, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
Solid Biosciences Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| ALEC | Alector | $97.06M | $15.89M |
| RVMD | Revolution Medicines, Inc. Warrant | $11.58M | - |
| STOK | Stoke Therapeutics | $8.78M | $4.22M |
| MOLN | Molecular Partners | $7.04M | $2.74M |
| IPSC | Century Therapeutics | $2.23M | $771.00K |
| BCEL | Atreca | $770.00K | $80.00K |
| ANEB | Anebulo Pharmaceuticals | - | - |
| CGEM | Cullinan Oncology | - | - |
| BDTX | Black Diamond Therapeutics | - | - |
| CCCC | C4 Therapeutics | - | - |
| CABA | Cabaletta Bio | - | - |
| PASG | Passage Bio | - | - |
| ACRV | Acrivon Therapeutics | - | - |
| PMVP | PMV Pharmaceuticals | - | - |
| MLYS | Mineralys Therapeutics | - | - |
| LRMR | Larimar Therapeutics | - | - |
| GLUE | Monte Rosa Therapeutics | - | $4.70M |
| SLDB | Solid Biosciences | - | - |
| EWTX | Edgewise Therapeutics | - | - |
SLDB Revenue FAQ
What is Solid Biosciences’s yearly revenue?
Solid Biosciences's yearly revenue for 2023 was $0, representing a decrease of -100.00% compared to 2022. The company's yearly revenue for 2022 was $8.09M, representing a decrease of -40.57% compared to 2021. SLDB's yearly revenue for 2021 was $13.62M, representing an increase of 100.00% compared to 2020.
What is Solid Biosciences’s quarterly revenue?
Solid Biosciences's quarterly revenue for Q2 2024 was $0, a 100.00% increase from the previous quarter (Q1 2024), and a 0% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $0, a -100.00% decrease from the previous quarter (Q4 2023), and a 0% increase year-over-year (Q1 2023). SLDB's quarterly revenue for Q4 2023 was $4.74M, a 100.00% increase from the previous quarter (Q3 2023), and a -41.49% decrease year-over-year (Q4 2022).
What is Solid Biosciences’s revenue growth rate?
Solid Biosciences's revenue growth rate for the last 3 years (2021-2023) was -100.00%, and for the last 5 years (2019-2023) was 0%.